{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:47:32Z","timestamp":1775890052266,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s10875-023-01617-1","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T02:02:21Z","timestamp":1703037741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Letermovir for CMV Prophylaxis in Very High-Risk Pediatric Hematopoietic Stem Cell Transplantation Recipients for Inborn Errors of Immunity"],"prefix":"10.1007","volume":"44","author":[{"given":"Thibaut","family":"C\u00e9sar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh P.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Klifa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Castelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"L\u00e9vy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Chbihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Courteille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Moshous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micka\u00ebl","family":"Alligon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Leruez-Ville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Frange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-0935","authenticated-orcid":false,"given":"B\u00e9n\u00e9dicte","family":"Neven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"1617_CR1","doi-asserted-by":"publisher","unstructured":"Ljungman P, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin Infect Dis off Publ Infect Dis Soc Am. 2014;59(4):473\u201381. https:\/\/doi.org\/10.1093\/cid\/ciu364.","DOI":"10.1093\/cid\/ciu364"},{"key":"1617_CR2","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2147\/IDR.S180908","volume":"12","author":"GE Helou","year":"2019","unstructured":"Helou GE, Razonable RR. Letermovir for the prevention of cytomegalovirus Infection and Disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019;12:1481\u201391. https:\/\/doi.org\/10.2147\/IDR.S180908.","journal-title":"Infect Drug Resist"},{"key":"1617_CR3","doi-asserted-by":"publisher","unstructured":"Green ML et al. \u2018CMV Viral Load and Mortality after Hematopoietic Cell Transplantation: A Cohort Study in the Era of Preemptive Therapy\u2019, Lancet Haematol. 2016;3(3):e119\u2013e127 https:\/\/doi.org\/10.1016\/S2352-3026(15)00289-6.","DOI":"10.1016\/S2352-3026(15)00289-6"},{"key":"1617_CR4","doi-asserted-by":"publisher","unstructured":"Lischka P et al. \u2018In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246\u2019, Antimicrob. Agents Chemother. 2010;54(3):1290\u20131297. https:\/\/doi.org\/10.1128\/AAC.01596-09.","DOI":"10.1128\/AAC.01596-09"},{"key":"1617_CR5","doi-asserted-by":"publisher","unstructured":"Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. \u2018The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase \u25bf\u2019, J. Virol. 2011;85(20):10884\u201310893. https:\/\/doi.org\/10.1128\/JVI.05265-11.","DOI":"10.1128\/JVI.05265-11"},{"key":"1617_CR6","doi-asserted-by":"publisher","unstructured":"Prohn M et al. \u2018Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients\u2019, CPT Pharmacomet. Syst. Pharmacol. 2021;10(3):255\u2013267. https:\/\/doi.org\/10.1002\/psp4.12593.","DOI":"10.1002\/psp4.12593"},{"key":"1617_CR7","unstructured":"Merck & Co. Inc., \u2018Prevymis\u2122 prescribing information.\u2019 2019. Accessed: Feb. 12, 2020. [Online]. Available: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_pi.pdf."},{"key":"1617_CR8","doi-asserted-by":"publisher","unstructured":"Marty FM et al. \u2018Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation\u2019, N. Engl. J. Med. 2017;377(25):2433\u20132444. https:\/\/doi.org\/10.1056\/NEJMoa1706640.","DOI":"10.1056\/NEJMoa1706640"},{"key":"1617_CR9","doi-asserted-by":"publisher","unstructured":"Vyas A, Raval AD, Kamat S, LaPlante K, Tang Y, Chemaly RF. Real-world outcomes Associated with Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic hematopoietic cell transplant recipients: a systematic review and Meta-analysis of Observational studies. Open Forum Infect Dis.  2022;10(1):ofac687. https:\/\/doi.org\/10.1093\/ofid\/ofac687.","DOI":"10.1093\/ofid\/ofac687"},{"key":"1617_CR10","doi-asserted-by":"publisher","unstructured":"Kuhn A et al. \u2018Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis\u2019, Transplant. Cell. Ther. 2023;29(1):62.e1-62.e4. https:\/\/doi.org\/10.1016\/j.jtct.2022.10.005.","DOI":"10.1016\/j.jtct.2022.10.005"},{"key":"1617_CR11","doi-asserted-by":"publisher","unstructured":"Richert-Przygonska M et al. \u2018Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation\u2019, Anticancer Res. 2022;42(7):3607\u20133612. https:\/\/doi.org\/10.21873\/anticanres.15848.","DOI":"10.21873\/anticanres.15848"},{"key":"1617_CR12","doi-asserted-by":"publisher","unstructured":"Cheng C-N, Li S-S, Yeh Y-H, Shen C-F, Chen J-S. \u2018Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan\u2019, J. Microbiol. Immunol. Infect. Wei Mian Yu Gan Ran Za Zhi. 2022;55(2):323\u2013327. https:\/\/doi.org\/10.1016\/j.jmii.2022.01.002.","DOI":"10.1016\/j.jmii.2022.01.002"},{"key":"1617_CR13","doi-asserted-by":"publisher","unstructured":"Styczy\u0144ski J, et al. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplant. 2021;56(5):1171\u20139. https:\/\/doi.org\/10.1038\/s41409-020-01166-w.","DOI":"10.1038\/s41409-020-01166-w"},{"key":"1617_CR14","doi-asserted-by":"publisher","unstructured":"K\u00f6rholz KF et al. \u2018Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients\u2019, Paediatr. Drugs. 2023;25(2):225\u2013232. https:\/\/doi.org\/10.1007\/s40272-022-00547-6.","DOI":"10.1007\/s40272-022-00547-6"},{"key":"1617_CR15","doi-asserted-by":"publisher","unstructured":"Strenger V et al. \u2018Letermovir in paediatric HSCT recipients\u2019, J. Antimicrob. Chemother. 201974(9):2820\u20132821. https:\/\/doi.org\/10.1093\/jac\/dkz218.","DOI":"10.1093\/jac\/dkz218"},{"key":"1617_CR16","doi-asserted-by":"publisher","unstructured":"P\u00e9rez Mar\u00edn M et al. \u2018Compassionate Use of Letermovir in a 2-Year-Old Immunocompromised Child With Resistant Cytomegalovirus Disease\u2019, J. Pediatr. Infect. Dis. Soc. 2020;9(1):96\u201399. https:\/\/doi.org\/10.1093\/jpids\/piz033.","DOI":"10.1093\/jpids\/piz033"},{"key":"1617_CR17","doi-asserted-by":"publisher","unstructured":"Daukshus NP et al. \u2018Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation\u2019, J. Pediatr. Infect. Dis. Soc. 2022;11(7):337\u2013340. https:\/\/doi.org\/10.1093\/jpids\/piac017.","DOI":"10.1093\/jpids\/piac017"},{"key":"1617_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.2147\/IDR.S296927","volume":"14","author":"A Chiereghin","year":"2021","unstructured":"Chiereghin A, et al. Off-label use of Letermovir as preemptive anti-cytomegalovirus therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant. Infect Drug Resist. 2021;14:1185\u201390. https:\/\/doi.org\/10.2147\/IDR.S296927.","journal-title":"Infect Drug Resist"},{"key":"1617_CR19","doi-asserted-by":"publisher","unstructured":"Bateman CM, Kesson A, Powys M, Wong M, Blyth E. \u2018Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies\u2019, Viruses. 2021;13(10):2001. https:\/\/doi.org\/10.3390\/v13102001.","DOI":"10.3390\/v13102001"},{"issue":"11","key":"1617_CR20","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1007\/s00431-022-04614-5","volume":"181","author":"Tdel Rosal","year":"2022","unstructured":"Rosal Tdel, et al. Impact of cytomegalovirus Infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity. Eur J Pediatr. 2022;181(11):3889\u201398. https:\/\/doi.org\/10.1007\/s00431-022-04614-5.","journal-title":"Eur J Pediatr"},{"key":"1617_CR21","doi-asserted-by":"publisher","unstructured":"Ljungman P, et al. Definitions of cytomegalovirus Infection and Disease in transplant patients for use in clinical trials: table 1. Clin Infect Dis. 2017;64(1):87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668.","DOI":"10.1093\/cid\/ciw668"},{"issue":"7","key":"1617_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1248\/cpb.c21-00142","volume":"69","author":"T Belabbas","year":"2021","unstructured":"Belabbas T, Yamada T, Tsuchiya Y, Suetsugu K, Egashira N, Ieiri I. Development and full validation of a Bioanalytical Method for quantifying letermovir in human plasma using Ultra-performance Liquid Chromatography coupled with Mass Spectrometry. Chem Pharm Bull (Tokyo). 2021;69(7):646\u201351. https:\/\/doi.org\/10.1248\/cpb.c21-00142.","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"1","key":"1617_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cpdd.388","volume":"7","author":"D Kropeit","year":"2018","unstructured":"Kropeit D, von Richter O, Stobernack H-P, R\u00fcbsamen-Schaeff H, Zimmermann H. Pharmacokinetics and safety of Letermovir Coadministered with Cyclosporine A or Tacrolimus in healthy subjects. Clin Pharmacol Drug Dev. 2018;7(1):9\u201321. https:\/\/doi.org\/10.1002\/cpdd.388.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"1617_CR24","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/cpdd.1081","volume":"11","author":"K Asari","year":"2022","unstructured":"Asari K, et al. Pharmacokinetics, Safety, and tolerability of Letermovir following single- and multiple-dose administration in healthy Japanese subjects. Clin Pharmacol Drug Dev. 2022;11(8):938\u201348. https:\/\/doi.org\/10.1002\/cpdd.1081.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1617_CR25","doi-asserted-by":"publisher","unstructured":"Rastogi S, et al. Clinical and economic impact of Cytomegalovirus Infection among children undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(6):1253\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.11.028.","DOI":"10.1016\/j.bbmt.2018.11.028"},{"key":"1617_CR26","doi-asserted-by":"publisher","unstructured":"Laberko A et al. \u2018Mismatched related vs matched unrelated donors in TCR\u03b1\u03b2\/CD19-depleted HSCT for primary immunodeficiencies\u2019, Blood. 2019;134(20):1755\u20131763. https:\/\/doi.org\/10.1182\/blood.2019001757.","DOI":"10.1182\/blood.2019001757"},{"key":"1617_CR27","doi-asserted-by":"publisher","unstructured":"Huntley D, et al. Features of Cytomegalovirus DNAemia blips in Allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2020;26(5):972\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.015.","DOI":"10.1016\/j.bbmt.2020.01.015"},{"key":"1617_CR28","doi-asserted-by":"publisher","unstructured":"Ljungman P et al. \u2018A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation\u2019, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2020;70(8):1525\u20131533. https:\/\/doi.org\/10.1093\/cid\/ciz490.","DOI":"10.1093\/cid\/ciz490"},{"key":"1617_CR29","doi-asserted-by":"publisher","unstructured":"Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. Antiviral Res. 2017;148:1\u20134. https:\/\/doi.org\/10.1016\/j.antiviral.2017.10.019.","DOI":"10.1016\/j.antiviral.2017.10.019"},{"key":"1617_CR30","unstructured":"Merck, Sharp, Dohme LLC. \u2018Extension of Letermovir (LET) from day 100 to Day 200 post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in hematopoietic stem cell transplant (HSCT) participants (MK-8228-040)\u2019. ClinicalTrials.gov Identifier: NCT03930615."},{"key":"1617_CR31","doi-asserted-by":"publisher","unstructured":"Zamora D et al. \u2018Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation\u2019, Blood. 2021;138(1):34\u201343. https:\/\/doi.org\/10.1182\/blood.2020009396.","DOI":"10.1182\/blood.2020009396"},{"key":"1617_CR32","doi-asserted-by":"publisher","unstructured":"Zavaglio F, et al. Human cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients. J Clin Virol. Aug. 2023;165:105519. https:\/\/doi.org\/10.1016\/j.jcv.2023.105519.","DOI":"10.1016\/j.jcv.2023.105519"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01617-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01617-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01617-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T04:17:17Z","timestamp":1706674637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01617-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1617"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01617-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3252427\/v1","asserted-by":"object"}]},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"14 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Research Ethics Committee of Assistance Publique-Hopitaux de Paris (CERAPHP) (Date 06\/06\/2023 \/ IRB registration No 00011928).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study, or from their parents or legal guardian.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed consent was obtained from all individual participants included in the study, or from their parents or legal guardian.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"P.F. has received honoraria and travel grants from MSD France, ViiV Healthcare, Janssen Cilag, Gilead Sciences, Takeda and AiCuris for participation in advisory boards, educational programs, and conferences. G.P. has received honoraria and travel grants from MSD France, ViiV Healthcare, Gilead Sciences and Takeda for participation in advisory boards, educational programs, and conferences. The other authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6"}}